Sensei Biotherapeutics, Inc. announced a 1-for-20 reverse stock split of its common stock, effective June 16, 2025, following approval from its stockholders. This move aims to ensure compliance with ...
Sensei Biotherapeutics (SNSE) announced results from the dose expansion portion of its Phase 1/2 trial evaluating solnerstotug, a conditionally active monoclonal antibody targeting VISTA. The data ...
Toronto, April 29, 2024 (GLOBE NEWSWIRE) -- TORONTO, CANADA, April 23, 2024 (Globenewswire) -- Sensei Labs announces the launch of AI in its award-winning Enterprise Orchestration platform, Conductor.
Sensei Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company offers PIKTOR, an investigational ...
BOSTON, June 13, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results